Logo

American Heart Association

  1
  0


Final ID: WMP89

Association of thrombectomy with clinical outcomes in elderly patients presenting beyond 24 hours of last known well – A secondary analysis of SELECT LATE study

Abstract Body: Introduction: Randomized clinical trials have demonstrated efficacy and safety of endovascular thrombectomy (EVT) among patients presenting up to 24 hours of last known well (LKW). Recent reports have suggested EVT could result in better functional outcomes with acceptable risk profile even in patients presenting beyond 24 hours of LKW, but exploration of the role of EVT in elderly patients presenting beyond 24 hours is limited.
Methods: We aimed to evaluate functional and safety outcomes for EVT in patients with age ≥80y with a large vessel occlusion (LVO) beyond 24 hours of LKW, from a pooled, international cohort (17 centers across US, Spain, Australia and New Zealand) between 7/2012 and 12/2021. Primary outcome was a shift on modified Rankin Scale score at 90-day follow-up.
Results: Of 301 included, 88 (53 EVT, 35 medical management MM) were aged ≥80y, with 57 females and 21 nonagenarians. Median(IQR) NIHSS - 17.5 (11-22),CT ASPECTS - 7(4-9), ischemic core 5.5 (0-26) ml. Overall, as age increased, clinical outcomes worsened (acOR: 0.64, 95% CI: 0.55-0.74, p<0.001 per 10 year increment). However, EVT was associated with a shift towards better functional outcome among patients with age≥80y (acOR: 8.31, 95% CI:2.80-24.68, p<0.001) and among patients with age<80y (acOR: 2.11, 95% CI: 1.22-3.66, p=0.008), with a significant interaction (p-int:0.047 – fig1) suggesting higher improvement within octogenarians. Estimates of Functional independence (EVT: 27% vs MM: 6%, aOR: 11.86, 95% CI: 1.75-80.28, p=0.011) and mortality (EVT: 42% vs MM: 71%, aOR: 0.16, 95% CI: 0.05-0.52, p=0.003) also favored EVT, with similar results obtained using inverse probability of treatment weights [Table 1]. 4 patients within EVT arm and no patients within MM arm developed symptomatic ICH. Among octogenarians receiving EVT, lower presentation NIHSS (aOR: 0.77, 95% CI: 0.64-0.92, p=0.003 per point increment) and presence of M2 occlusion (aOR: 11.01, 95% CI: 1.15-105.36, p=0.037 were independently associated with functional independence at 90-day follow-up), but not time to procedure (aOR: 0.99, 95% CI: 0.96-1.02, p=0.64, fig2).
Conclusions: In a pooled international cohort of octogenarians who presented beyond 24 hours with an LVO, EVT was associated with better functional outcomes, higher functional independence and lower mortality. Lower stroke severity and presence of M2 occlusion were independently associated with functional independence at 90-day after EVT.
  • Pujara, Deep  ( University Hospitals , Cleveland , Ohio , United States )
  • Sitton, Clark  ( UT Houston McGovern Medical School , Houston , Texas , United States )
  • Wu, Teddy  ( CHRISTCHURCH HOSPITAL , Christchurch , New Zealand )
  • Blasco, Jordi  ( Hospital Clínic de Barcelona , Barcelona , Spain )
  • Sangha, Navi  ( KAISER PERMANENTE , Los Aeles , California , United States )
  • Arenillas, Juan  ( HOSPITAL CLINICO UNIV VALLADOLID , Valladolid , Spain )
  • Opaskar, Amanda  ( University Hospitals , Cleveland , Ohio , United States )
  • Mccullough-hicks, Margy  ( University of Minnesota , Saint Paul , Minnesota , United States )
  • Wallace, Adam  ( Aurora BayCare Medical Center , Milwaukee , Wisconsin , United States )
  • Arthur, Adam  ( Semmes-Murphey Neurological Clinic , Memphis , Tennessee , United States )
  • Grotta, James  ( UT Houston McGovern Medical School , Houston , Texas , United States )
  • Kleinig, Timothy  ( Royal Adelaide Hospital , Adelaide , South Australia , Australia )
  • Parsons, Mark  ( Liverpool hospital , Liverpool Bc 1871 , New South Wales , Australia )
  • Ribo, Marc  ( HOSPITAL VALL D HEBRON , Barcelona , Spain )
  • Albers, Gregory  ( Stanford University Medical Center , Stanford , California , United States )
  • Campbell, Bruce  ( Royal Melbourne Hospital , Parkville , Victoria , Australia )
  • Sarraj, Amrou  ( University Hospitals Cleveland Med , Cleveland , Ohio , United States )
  • Hassan, Ameer  ( UTRGV - VALLEY BAPTIST MEDICAL CENT , Harlingen , Texas , United States )
  • Cardona, Pedro  ( BELLVITGE HOSPITAL , Barcelona , Spain )
  • Ortega-gutierrez, Santiago  ( UNIVERSITY OF IOWA HOSPITALS , Iowa City , Iowa , United States )
  • Abraham, Michael  ( UNIVERSITY OF KANSAS HOSPITAL , Kansas City , Missouri , United States )
  • Manning, Nathan  ( SYDNEY NEUROINTERVENTION SPECIALIST , Sydney , New South Wales , Australia )
  • Goyal, Nitin  ( Semmes Murphey Clinic , Memphis , Tennessee , United States )
  • Blackburn, Spiros  ( University of Texas Houston Health Science Center , Houston , Texas , United States )
  • Author Disclosures:
    Deep Pujara: DO NOT have relevant financial relationships | clark sitton: DO NOT have relevant financial relationships | Teddy Wu: DO NOT have relevant financial relationships | Jordi Blasco: No Answer | Navi Sangha: DO NOT have relevant financial relationships | Juan Arenillas: DO have relevant financial relationships ; Research Funding (PI or named investigator):Spanish Ministry of Science:Active (exists now) ; Speaker:Medtronic:Past (completed) ; Advisor:Medtronic:Active (exists now) ; Advisor:BMS Pfizer:Past (completed) ; Advisor:Astra Zeneca:Past (completed) ; Research Funding (PI or named investigator):Astra Zeneca:Past (completed) ; Research Funding (PI or named investigator):Castilla y León Department of Health:Past (completed) | Amanda Opaskar: No Answer | Margy McCullough-Hicks: DO have relevant financial relationships ; Researcher:American Academy of Neurology:Active (exists now) | Adam Wallace: DO NOT have relevant financial relationships | Adam Arthur: DO have relevant financial relationships ; Consultant:Arsenal:Active (exists now) ; Individual Stocks/Stock Options:Scientia:Active (exists now) ; Consultant:Stryker:Active (exists now) ; Consultant:Siemens:Active (exists now) ; Consultant:Scientia:Active (exists now) ; Consultant:NV Medtech:Active (exists now) ; Consultant:Mendaera:Active (exists now) ; Consultant:Perfuze:Active (exists now) ; Consultant:Penumbra:Active (exists now) ; Consultant:Nuvascular:Active (exists now) ; Consultant:Neuros:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Inretio:Active (exists now) ; Consultant:Cerenovus:Active (exists now) ; Consultant:Balt:Active (exists now) | James Grotta: DO have relevant financial relationships ; Consultant:Frazer Ltd:Active (exists now) ; Advisor:Prolong Pharma:Active (exists now) ; Advisor:Acticor:Active (exists now) ; Advisor:Diamedica:Active (exists now) | Timothy Kleinig: DO have relevant financial relationships ; Research Funding (PI or named investigator):Astra Zeneca:Active (exists now) | Mark Parsons: DO NOT have relevant financial relationships | Marc Ribo: DO NOT have relevant financial relationships | Gregory Albers: DO have relevant financial relationships ; Consultant:iSchemaView:Active (exists now) ; Individual Stocks/Stock Options:iSchemaView:Active (exists now) ; Consultant:Genentech:Past (completed) | Bruce Campbell: DO NOT have relevant financial relationships | Amrou Sarraj: DO have relevant financial relationships ; Research Funding (PI or named investigator):Stryker Neurovascular:Active (exists now) | Ameer Hassan: DO have relevant financial relationships ; Consultant:Medtronic, Microvention, Stryker, Penumbra, Cerenovus, Genentech, GE Healthcare, Scientia, Balt, Viz.ai , Insera therapeutics, Proximie, NeuroVasc, NovaSignal, Vesalio, Rapid Medical, Imperative Care, Galaxy Therapeutics, Route 92, Perfuze, CorTech, Shockwave and Xcath:Active (exists now) | Pedro Cardona: DO NOT have relevant financial relationships | Santiago Ortega-Gutierrez: DO have relevant financial relationships ; Consultant:Medtronic:Active (exists now) ; Research Funding (PI or named investigator):Methinks:Active (exists now) ; Research Funding (PI or named investigator):Stryker:Active (exists now) ; Research Funding (PI or named investigator):MEdtronic:Active (exists now) ; Researcher:PCORI:Active (exists now) ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Consultant:Stryker:Active (exists now) | Michael Abraham: DO have relevant financial relationships ; Consultant:Stryker Neurovascular:Active (exists now) ; Consultant:Q'Apel Medical:Active (exists now) | Nathan Manning: DO NOT have relevant financial relationships | Nitin Goyal: DO NOT have relevant financial relationships | Spiros Blackburn: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Neuroendovascular Moderated Poster Tour I

Wednesday, 02/05/2025 , 06:00PM - 07:00PM

Moderated Poster Abstract Session

More abstracts on this topic:
Coil Embolization or Clipping for Elderly Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis

Rossi Yohanna, Bolner Gabriel, Costa Dall'acqua Jonathan, Dolovitsch De Oliveira Fabiana, Vincenzi Zacaria Lucas, Denicol Taís Luise

Association Between In-hospital Cardiac Arrest Incidence and Survival in Older Patients

Nathani Rohit, Li Qiang, Nguyen Cathy, Koshy Thomas, Hall Hurst, Mentias Amgad, Chan Paul, Girotra Saket

More abstracts from these authors:
Mediation of Successful Reperfusion Effect on Independent Ambulation Through Infarct Growth Reduction in Patients with Large Strokes: A Secondary Analysis of SELECT2 Trial

Sarraj Amrou, Grotta James, Ribo Marc, Sitton Clark, Hill Michael, Campbell Bruce, Pujara Deep, Churilov Leonid, Johns Hannah Tabitha, Hassan Ameer, Abraham Michael, Hussain Shazam, Chen Michael, Ortega-gutierrez Santiago

Site vs Core-lab CT ASPECTS read in the SELECT2 trial – assessment of trial eligibility and EVT treatment effect

Alshaibi Faisal, Saidi Yazid, Albedaiwi Mohammed, Yaghmoor Bassam, Al Mostaneer Alhassin, Johns Hannah Tabitha, Churilov Leonid, Parsons Mark, Grotta James, Ribo Marc, Hill Michael, Pujara Deep, Campbell Bruce, Sarraj Amrou, Hassan Ameer, Abraham Michael, Sitton Clark, Hussain Muhammad, Nguyen Thanh, Ortega-gutierrez Santiago, Chen Michael

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)